1. Volume 13, Issue 3, Pages 213-225 (July 2015)
Efficacy and Safety of Topical 0.05% Cyclosporine Eye Drops in the Treatment of Dry Eye Syndrome: A Systematic Review and Meta-analysis 
Kelvin H. Wan, MBChB, Li Jia Chen, MRCSEd(Ophth), PhD, Alvin L. Young, MMedSc (Hons), FRCSIrel 
The Ocular Surface 
Volume 13, Issue 3, Pages (July 2015)
DOI: /j.jtos
Copyright © 2015 Elsevier Inc. Terms and Conditions

2. Figure 1
Flow chart showing selection of RCTs for inclusion in this meta-analysis. CENTRAL=Cochrane Central Register of Controlled Trials; WHO ICTRP=World Health Organization International Clinical Trials Registry Platform; RCT=randomized control trial; DES=dry eye syndrome. *Of these 808 studies, 457 were not related to dry eye human subjects (i.e., other ocular or non-ocular autoimmune diseases that were not DES where cyclosporine was used; conditions where DES can be part of the manifestation but were not the main objective of the studies, i.e., Sjögren syndrome, Stevens-Johnson syndrome; or animal studies); 139 involved DES where topical 0.05% cyclosporine was not the intervention; 124 were review articles on DES or the general role of cyclosporine on autoimmune diseases; 42 were case series or observational studies where no control group was used; 31 did not present outcomes relevant to this meta-analysis in the abstracts; and 15 were not RCTs.
The Ocular Surface  , DOI: ( /j.jtos )
Copyright © 2015 Elsevier Inc. Terms and Conditions

3. Figure 2
A. Risk of bias summary: authors' judgments about each risk of bias item for each included study. B. Risk of bias graph: authors' judgments about each risk of bias item presented as percentages across all included studies.
The Ocular Surface  , DOI: ( /j.jtos )
Copyright © 2015 Elsevier Inc. Terms and Conditions

4. Figure 3
Ocular surface disease index (OSDI) scores in cyclosporine A and control groups. CsA=cyclosporine; SD=standard deviation; IV=inverse variance; CI=confidence interval.
The Ocular Surface  , DOI: ( /j.jtos )
Copyright © 2015 Elsevier Inc. Terms and Conditions

5. Figure 4
Tear film break-up time (TFBUT) values in cyclosporine A and control groups. CsA=cyclosporine; SD=standard deviation; IV=inverse variance; CI=confidence interval.
The Ocular Surface  , DOI: ( /j.jtos )
Copyright © 2015 Elsevier Inc. Terms and Conditions

6. Figure 5
Schirmer test (without anesthesia) in cyclosporine A and control groups. CsA=cyclosporine; SD=standard deviation; IV=inverse variance; CI=confidence interval.
The Ocular Surface  , DOI: ( /j.jtos )
Copyright © 2015 Elsevier Inc. Terms and Conditions

7. Figure 6
Schirmer test (with anesthesia) in cyclosporine A and control groups. CsA=cyclosporine; SD=standard deviation; IV=inverse variance; CI=confidence interval.
The Ocular Surface  , DOI: ( /j.jtos )
Copyright © 2015 Elsevier Inc. Terms and Conditions

8. Figure 7
Goblet cell density in cyclosporine A and control groups. CsA=cyclosporine; SD=standard deviation; Std. Mean Difference=standardized mean difference; IV=inverse variance; CI=confidence interval.
The Ocular Surface  , DOI: ( /j.jtos )
Copyright © 2015 Elsevier Inc. Terms and Conditions

9. Figure 8
Corneal fluorescein staining in cyclosporine A and control groups. CsA=cyclosporine; SD=standard deviation; Std. Mean Difference=standardized mean difference; IV=inverse variance; CI=confidence interval.
The Ocular Surface  , DOI: ( /j.jtos )
Copyright © 2015 Elsevier Inc. Terms and Conditions

10. Figure 9
Treatment-related adverse effects in cyclosporine A and control groups. CsA=cyclosporine; SD=standard deviation; M-H=Mantel-Haenszel, CI=confidence interval.
The Ocular Surface  , DOI: ( /j.jtos )
Copyright © 2015 Elsevier Inc. Terms and Conditions